



2018 Alliance Spring Group Meeting
Date Friday, May 11, 2018
Loews Chicago O'Hare Hotel
Time 8:00 –10:00 am
Pollock A

Radiation Oncology Committee Meeting Agenda

Chair: Jeff Bogart

NEW

A031701 PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (DDGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS
 KWOK

Description

Presenter

Lung Cancer

- **AFT- 16: Induction PDL-1 inhibition Stage III NSCLC** *Urbanic*
- **AFT-07** Veliparib + ChemoRT Stage III NSCLC *Salama*
- **C 30610:** Limited Stage Small Cell Intergroup Trial – *Bogart*
- **NRG CC003:** PCI with or without Hippocampal Avoidance for SCLC *Grecula*

Breast Cancer

- **Alliance A221505 Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction** *Poppe*
- **A011202** The role of axillary lymph node dissection (cT1-3 N1) for positive sentinel lymph node disease after neoadjuvant chemotherapy
- **NRG** Oligometastatic Trials *Salama*

CNS

- **CE.7** SRS vs WBRT for Multiple Brain Metastases
- **A221208** Ph IIR Radionecrosis Steroids vs Bevacizumab
- **N0577** Ph III AG CODELETED RT + PCV vs RT+TMZ
- **A071102** Phase II/III GBM Adjuvant TMZ ± Veliparib

GI Cancer

- **A021501**, “Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated RT for Borderline Resectable Adenocarcinoma of the Head of the Pancreas”
- **N 1048** Selective use of radiation for locally advanced rectal cancer, 1,000 patients enrolled as of March 29. *Mamon*

Skin

- **A091605** includes stereotactic body radiotherapy and pembrolizumab in advanced **merkel cell carcinoma** *Chmur*

IROC Update